
Memorial Sloan Kettering Cancer Center
Investments
6Portfolio Exits
2Funds
1Partners & Customers
10About Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center is committed to patient care, research, and educational programs. Its education programs train future physicians and scientists.

Want to inform investors similar to Memorial Sloan Kettering Cancer Center about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Research containing Memorial Sloan Kettering Cancer Center
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Memorial Sloan Kettering Cancer Center in 1 CB Insights research brief, most recently on Jan 19, 2021.

Jan 19, 2021
27 Corporate Innovation Labs In HealthcareLatest Memorial Sloan Kettering Cancer Center News
Jan 31, 2023
One of Cody’s latest projects is a docuseries, “A Life Worth Running,” about Peter Kirk, an acute myeloid leukemia survivor and CEO of Sermo. by Eric BergerAdded 55 minutes ago NEW YORK: Jon Cody had spent almost 15 years working in television and video streaming for companies such as Fox and Hulu when in 2021 he launched a movie company focused on a niche: health and healthcare. "There's so much information and misinformation out there [when people search for information on the internet]," Cody said. "If you did find a video that was interesting, it was often very clinical." His goal, he said, is "to bring Hollywood storytelling into healthcare." One of Cody's latest projects is a docuseries, "A Life Worth Running," about Peter Kirk, an acute myeloid leukemia survivor and the CEO of Sermo, which provides a social network for physicians. Only about 30% of U.S. adults with that cancer survive more than five years, according to Yale Medicine. The three-part series tells the story of Kirk almost dying from the double whammy of leukemia and double lung pneumonia, receiving a stem-cell transplant and deciding to run the New York City Marathon. We also see Cody, now cured of the disease, reach out to his donor and meet him. PRWeek conducted a phone interview with Cody to learn more about the series and his company. What made you decide that there was a need for a company that offered Hollywood storytelling to healthcare companies? Part of why we started it is personal. I have two sons who are on the Autism spectrum. Everyone starts healthcare with Dr. Google, and you're running down a YouTube rabbit hole of stuff where you don't know if it's good or bad. The more that you can plain-English health and healthcare, and the more that you can get beyond a simple doctor to trusted sources like nurses, like caregivers, like patients. We felt like it was a more powerful message to people seeking information." How does your company's business model work? Do healthcare organizations or companies pay you to produce films? Yeah, they do. Some pay us just to do what they want to do. Some will pay us on the sponsorship of things that we want to do as a studio, and then there's that middle ground, like with Sermo, where it's a pure co-production, where we are developing intellectual property together and co-owning the story and the ancillary content. You can imagine a story like this could be a scripted feature film. What do you think a film like this does for Sermo or Memorial Sloan Kettering Cancer Center? (Kirk recovered at Sloan Kettering and committed to donate $1 million to the hospital). We want to bring a little more awareness to who they are. It does raise the brand, and a lot of what we said to Sermo and Memorial Sloan Kettering is that you want to activate your talent. You actually have talent within that building. And, yes, some of them are on TikTok, but a lot of it is activating those people in a way where they are actually produced. And there's kind of a third angle: how do you use video for research purposes? You see a lot of public health grants go to medical research institutions, but they haven't yet used storytelling and video to improve outcomes. Is there a particular skill set or technique that is required to make healthcare films as compared to films about other industries or other sorts of entertainment movies? You need the appropriate people to make sure that there's medical accuracy, although that happens even on a show like "House." There are always consultants who play those roles, but I think ultimately the difference here for us is the voices of healthcare. A patient can speak in plain English, but you want to make sure that a medical professional — I don't want to say dumbs it down — but speaks on a level that the rest of us can understand. Subject Tags:
Memorial Sloan Kettering Cancer Center Investments
6 Investments
Memorial Sloan Kettering Cancer Center has made 6 investments. Their latest investment was in Blue Note Therapeutics as part of their Series A - II on September 9, 2021.

Memorial Sloan Kettering Cancer Center Investments Activity

Date | Round | Company | Amount | New? | Co-Investors | Sources |
---|---|---|---|---|---|---|
9/9/2021 | Series A - II | Blue Note Therapeutics | $5.2M | Yes | 5 | |
6/1/2021 | Series B | |||||
8/9/2019 | Series D | |||||
2/21/2018 | Series C | |||||
2/13/2018 | Series C |
Date | 9/9/2021 | 6/1/2021 | 8/9/2019 | 2/21/2018 | 2/13/2018 |
---|---|---|---|---|---|
Round | Series A - II | Series B | Series D | Series C | Series C |
Company | Blue Note Therapeutics | ||||
Amount | $5.2M | ||||
New? | Yes | ||||
Co-Investors | |||||
Sources | 5 |
Memorial Sloan Kettering Cancer Center Portfolio Exits
2 Portfolio Exits
Memorial Sloan Kettering Cancer Center has 2 portfolio exits. Their latest portfolio exit was ORIC Pharmaceuticals on April 24, 2020.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
---|---|---|---|---|---|
4/24/2020 | IPO | Public | 4 | ||
Date | 4/24/2020 | |
---|---|---|
Exit | IPO | |
Companies | ||
Valuation | ||
Acquirer | Public | |
Sources | 4 |
Memorial Sloan Kettering Cancer Center Acquisitions
1 Acquisition
Memorial Sloan Kettering Cancer Center acquired 1 company. Their latest acquisition was Ralph Lauren Center for Cancer Care and Prevention on August 08, 2018.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
---|---|---|---|---|---|---|
8/8/2018 | Acquired | 1 |
Date | 8/8/2018 |
---|---|
Investment Stage | |
Companies | |
Valuation | |
Total Funding | |
Note | Acquired |
Sources | 1 |
Memorial Sloan Kettering Cancer Center Fund History
1 Fund History
Memorial Sloan Kettering Cancer Center has 1 fund, including Fiona and Stanley Druckenmiller Presidential Innovation Fund.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
---|---|---|---|---|---|
Fiona and Stanley Druckenmiller Presidential Innovation Fund | $100M | 2 |
Closing Date | |
---|---|
Fund | Fiona and Stanley Druckenmiller Presidential Innovation Fund |
Fund Type | |
Status | |
Amount | $100M |
Sources | 2 |
Memorial Sloan Kettering Cancer Center Partners & Customers
10 Partners and customers
Memorial Sloan Kettering Cancer Center has 10 strategic partners and customers. Memorial Sloan Kettering Cancer Center recently partnered with Illuminare Biotechnologies on January 1, 2023.
Date | Type | Business Partner | Country | News Snippet | Sources |
---|---|---|---|---|---|
1/23/2023 | Partner | United States | The first-in-human clinical trial is being conducted at Memorial Sloan Kettering Cancer Center , along with collaborators from Illuminare Biotechnologies , in patients undergoing robot-assisted radical prostatectomy . | 1 | |
1/13/2023 | Partner | United States | NYSNA: ‘It’s not over’ as agreements usher in improved staffing ratios, wages The first phase of the partnership is expected to last throughout the year and will focus on physicians at MSK working with MediSys Health Network to enhance the onsite oncology program at Jamaica Hospital . | 1 | |
12/14/2022 | Partner | Israel | `` Despite enormous progress over decades , resistance to anti-cancer drugs continues to be a major problem in treating cancer , the second-leading cause of death globally , '' said Ayelet Dilion-Mashiah , Chief Executive Officer of NewStem Ltd. `` We are excited to work with the MSK Innovation Hub in a collaboration that will bring together experts with the deepest expertise and a common goal to improve the lives of people with cancer . '' | 2 | |
12/14/2022 | Partner | ||||
11/21/2022 | Vendor |
Date | 1/23/2023 | 1/13/2023 | 12/14/2022 | 12/14/2022 | 11/21/2022 |
---|---|---|---|---|---|
Type | Partner | Partner | Partner | Partner | Vendor |
Business Partner | |||||
Country | United States | United States | Israel | ||
News Snippet | The first-in-human clinical trial is being conducted at Memorial Sloan Kettering Cancer Center , along with collaborators from Illuminare Biotechnologies , in patients undergoing robot-assisted radical prostatectomy . | NYSNA: ‘It’s not over’ as agreements usher in improved staffing ratios, wages The first phase of the partnership is expected to last throughout the year and will focus on physicians at MSK working with MediSys Health Network to enhance the onsite oncology program at Jamaica Hospital . | `` Despite enormous progress over decades , resistance to anti-cancer drugs continues to be a major problem in treating cancer , the second-leading cause of death globally , '' said Ayelet Dilion-Mashiah , Chief Executive Officer of NewStem Ltd. `` We are excited to work with the MSK Innovation Hub in a collaboration that will bring together experts with the deepest expertise and a common goal to improve the lives of people with cancer . '' | ||
Sources | 1 | 1 | 2 |
Memorial Sloan Kettering Cancer Center Team
25 Team Members
Memorial Sloan Kettering Cancer Center has 25 team members, including current President, Paul A Marks.
Name | Work History | Title | Status |
---|---|---|---|
Paul A Marks | President | Current | |
Name | Paul A Marks | ||||
---|---|---|---|---|---|
Work History | |||||
Title | President | ||||
Status | Current |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.